NON-SMALL CELL LUNG CANCER (NSCLC), EGFR DOWNSTREAM PATHWAY ACTIVATION AND TKI TARGETED THERAPIES SENSITIVITY: EFFECT OF THE PLASMA MEMBRANE-ASSOCIATED NEU3.

Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3.

Adenocarcinoma of Non-Small Cell Lung Cancer (NSCLC) is a severe disease.Patients carrying EGFR mutations may benefit from EGFR targeted therapies (e.g.: gefitinib).Recently, it has been shown that sialidase NEU3 directly interacts and regulates EGFR.In this work, we investigate the effect of sialidase NEU3 overexpression on EGFR pathways activatio

read more